NASDAQ: MBRX Moleculin Biotech, Inc. 8-K

Moleculin presents cardiac safety data for Annamycin at major European cancer conference

Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read

2 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MBRX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 6:20 PM